Induction of posterior vitreous detachment (PVD) by non-enzymatic reagents concentrating on vitreous collagen liquefaction in addition to vitreoretinal adhesion
Induction of posterior vitreous detachment (PVD) by pharmacologic vitreolysis has been largely tried via using enzymatic reagents. Ocriplasmin has been the one FDA-approved medical reagent to this point. A number of hostile results of ocriplasmin have emerged, nevertheless, and the seek for various PVD-inducing reagents continues.
Since i) collagen kinds an necessary structural element of the vitreous, and ii) sturdy vitreo-retinal adhesions exist between the cortical vitreous and the interior limiting membrane (ILM) of the retina, an efficient PVD-inducing reagent would require each, vitreous liquefaction, and concurrent dehiscence of vitreoretinal adhesion, with out being poisonous to retinal cells. We designed a mixture of two reagents to realize these two aims; a triple helix-destabilizing collagen binding area (CBD), and a fusion of RGD (integrin-binding) tripeptide with CBD (RCBD) to facilitate separation of posterior cortical vitreous from retinal floor.
Based mostly on in vitro, ex-vivo, and in vivo experiments, we present {that a} mixture of CBD and RCBD shows potential for secure pharmacologic vitreolysis. Our findings assume significance in gentle of the truth that artificial RGD-containing peptides have already been used for inhibition of tumor cell invasion. Proteins akin to variants of collagen binding domains might have prolonged therapeutic makes use of sooner or later.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: CCL16 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 97 amino acids and having a molecular mass of 11.2 kDa. ;The CCL16 is purified by proprietary chromatographic techniques.
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - With BSA and Azide. The antibodies are raised in Mouse and are from clone LEC66. This antibody is applicable in E
Monoclonal HCC-4 / Liver Expressed Chemokine (LEC) Antibody - With BSA and Azide, Clone: LEC67
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - With BSA and Azide. The antibodies are raised in Mouse and are from clone LEC67. This antibody is applicable in E
Monoclonal HCC-4 / Liver Expressed Chemokine (LEC) Antibody - Without BSA and Azide, Clone: LEC66
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone LEC66. This antibody is applicable in E
Monoclonal HCC-4 / Liver Expressed Chemokine (LEC) Antibody - Without BSA and Azide, Clone: LEC67
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone LEC67. This antibody is applicable in E
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids.
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids.
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids.
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit
Description: This is Competitive Enzyme-linked immunosorbent assay for Antibody Detection.detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in serum, plasma and other biological fluids.
Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) ELISA Kit
Description: Enzyme-linked immunosorbent assay based on the Competitive Inhibition method for detection of Human Anti-Anti-Sperm Antibody Antibody (Anti-AsAb) in samples from serum, plasma and other biological fluids with no significant corss-reactivity with analogues from other species.
Applicability of ninhydrin as a fluorescent reagent for estimation of teicoplanin in human plasma utilizing salting-out assisted liquid-liquid extraction approach
The applicability of ninhydrin, a broadly used derivatizing reagent, for dedication of teicoplanin (TEIC) in its pure kind, pharmaceutical vials, and in human plasma was investigated. The introduced spectrofluorimetric methodology was based mostly on a condensation response between ninhydrin and the first amine group current in TEIC (within the presence of phenylacetaldehyde) to supply a extremely fluorescent product detected at 460 nm (λex ,390 nm). Calibration plots have been constructed within the focus vary 60-600 ng mL-1 with an excellent correlation coefficient of 0.9998 and a low detection restrict of 10.84 ng mL-1 .
The tactic was subjected to a bioanalytical validation research based on US-FDA suggestions. The proposed methodology was utilized for evaluation of TEIC in business vials with excessive restoration outcome 101.88 ± 1.11%. As well as, the methodology was utilized effectively for detection of TEIC in human plasma utilizing salting-out assisted liquid-liquid extraction approach (SALLE) with a restoration vary from 96.71 ± 1.08% to 97.71 ± 0.86%. SALLE is an efficient strategy used for extraction of TEIC from human plasma with out interferences utilizing ammonium sulphate. The proposed methodology is extremely really helpful to observe TEIC in medical laboratory samples and therapeutic drug monitoring programs.
Analysis of a brand new thromboplastin reagent STA-NeoPTimal on a STA R Max analyzer for the measurement of prothrombin time, worldwide normalized ratio and extrinsic issue ranges
Introduction: We aimed toward evaluating the efficiency of a brand new prothrombin time (PT) reagent (STA-NeoPTimal) with two different PT reagents (STA-Neoplastine R and STA-Neoplastine CI Plus) and the reference PT reagent utilized in our laboratory (ReadiPlasTin).
Strategies: Analysis consisted in intra- and interassay precision evaluation, dedication of sensitivity to unfractionated heparin (UFH) or enoxaparin in spiked samples and to direct oral anticoagulants (DOACs) in sufferers (n = 43). Methodology comparability of the four PT reagents, issue II, V, VII and X assays was examined on regular (n = 20) and irregular samples: VKA (n = 47), preoperative (n = 23), liver failure (n = 12) and burned sufferers (n = 37).
Outcomes: Analytical efficiency met producers’ standards for all reagents. All PT reagents gave correlation coefficients >0.eight and even >0.9 in lots of conditions. In some VKA samples, variations ≥ 0.5 INR models have been present in samples inside and above therapeutic ranges. For burned sufferers, PT correlations have been good however with some minimal bias (<5.0%) whereas issue assays gave very constant outcomes (R > .eight and primarily >0.9). As anticipated, poor responsiveness of the PT to DOAC concentrations was noticed with all 4 assays.
Conclusion: The STA-NeoPTimal confirmed comparable efficiency to ReadiPlasTin, making it appropriate for VKA management, detection of things II, V, VII, X deficiency and evaluation of liver illness coagulopathy. Nevertheless, for sufferers receiving VKA, some important variations have been noticed. We confirmed the shortcoming of the PT assay to detect residual DOAC concentrations. Lastly, burned sufferers outcomes confirmed that recombinant thromboplastins have been much less delicate to issue deficiencies compared to extraction thromboplastins.
Description: The CD80 antigen (B7, BB1) recognizes a 60 kDa transmembrane glycoprotein, member of the immunoglobulin family. This molecule shares with CD86 the capability to be the ligand for two structurally similar molecules expressed on T lymphocytes, CD28 and CD152 (CTLA-4). CD80 antigen is expressed on in vitro activated B lymphocytes. It is not expressed on the majority of resting B cells from peripheral blood but identifies a subpopulation of B cells that has been previously activated. The antigen is also expressed by HTLV-1 transformed T cells activated monocytes, and constitutively on dendritic cells. CD80 binding provides costimulatory signals for T cell activation.
Description: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).
Description: CD80, also known as B7-1, is a type I membrane protein that is a member of the immunoglobulin superfamily. Like the related protein CD86, this protein is expressed by antigen-presenting cells, and is the ligand for two proteins at the cell surface of T cells, CD28 and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Binding of this protein with CD28 antigen is a costimulatory signal for activation of the T-cell and induces T-cell proliferation and cytokine production. CTLA-4 binding negatively regulates T-cell activation and diminishes the immune response (1). Blocking the CTLA-4-CD80/CD86 interaction has been shown to enhance T-cell functions in acute lymphoblastomic leukemia (ALL), suggesting that this pathway may be an attractive target for future cancer immunotherapy (2).
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: Cluster of Differentiation 80 (also CD80 and B7-1) is a protein found on activated B cells and monocytes that provides a costimulatory signal necessary for T cell activation and survival. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. The CD80 genes encode B7-1 which are structurally similar members of the immunoglobulin superfamily expressed on a variety of hematopoietic cell types.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Description: T cell proliferation and lymphokine production are triggered by occupation of the TCR by antigen, followed by a costimulatory signal that is delivered by a ligand expressed on antigen presenting cells. The B7-related cell surface proteins CD80 (B7-1) and CD86 (B7-2) are expressed on antigen presenting cells bind the homologous T cell receptors CTLA-4 (cytotoxic T lymphocyte-associated protein-4) and CD28 and trigger costimulatory signals for optimal T cell activation. CTLA-4 shares 31% overall amino acid identity with CD28 and it has been proposed that CD28 and CTLA-4 are functionally redundant. SLAM is a novel receptor on T cells that, when engaged, potentiates T cell expansion in a CD28-independent manner. B7, also designated BB1, is another ligand or counter receptor for CD28 and CTLA-4 that is expressed on the antigen-presenting cell.
Human CD80/ T-lymphocyte activation antigen CD80 ELISA Kit
Description: CD80 Human Recombinant produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 216 amino acids (35-242a.a.) and having a molecular mass of 24.9kDa (Molecular size on SDS-PAGE will appear at approximately 28-40kDa).;CD80 is expressed with an 8 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Description: Description of target: The protein CD80(Cluster of Differentiation 80) is a molecule found on activated B cells and monocytes which provides a costimulatory signal necessary for T cell activation and survival. It is also known as B7-1. The cDNA for B7-1 predicts a type I membrane protein, i.e., one synthesized with a signal peptide that is cleaved upon translocation across the endoplasmic membrane. The protein is predicted to contain 2 extracellular domains structurally similar to those of Ig, a hydrophobic transmembrane region, and a short cytoplasmic domain. The CD80 and CD86 genes encode B7-1 and B7-2, respectively, which are structurally similar members of the immunoglobulin superfamily expressed on a variety of hematopoietic cell types. B7-1 and B7-2 provide a costimulatory signal to T cells by interacting with CD28 and CTLA4.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml
Description: Description of target: The protein encoded by this gene is a membrane receptor that is activated by the binding of CD28 or CTLA-4. The activated protein induces T-cell proliferation and cytokine production. This protein can act as a receptor for adenovirus subgroup B and may play a role in lupus neuropathy.;Species reactivity: Human;Application: ELISA;Assay info: ;Sensitivity: < 33pg/mL
Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.
Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.
Description: CD80 (B7-1) and CD86 (B7-2) together with their receptors CD28 and CTLA-4 constitute one of the dominant costimulatory pathways that regulate T cell and B cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20-100 fold higher affinity than CD28 and is involved in the down-regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up-regulated through interferon-gamma. B7-1 and B7-2 are both members of the immunoglobulin superfamily. It has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.
Description: A polyclonal antibody for detection of CD80 from Human. This CD80 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CD80 protein at amino acid sequence of 100-160
Description: A polyclonal antibody for detection of CD80 from Human. This CD80 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CD80 protein at amino acid sequence of 100-160
Description: A polyclonal antibody for detection of CD80 from Human. This CD80 antibody is for IHC-P, ELISA. It is affinity-purified from rabbit serum by affinity-chromatography using the specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from part region of human CD80 protein at amino acid sequence of 100-160
by 
